Lyell Immunopharma (NASDAQ:LYEL – Get Rating) had its price target trimmed by Morgan Stanley from $7.00 to $4.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock.
A number of other analysts have also recently issued reports on LYEL. The Goldman Sachs Group cut Lyell Immunopharma from a buy rating to a neutral rating and decreased their target price for the stock from $13.00 to $7.00 in a report on Friday, November 11th. HC Wainwright decreased their price target on Lyell Immunopharma from $12.00 to $11.00 in a report on Wednesday, November 9th.
Get
Lyell Immunopharma alerts:
Lyell Immunopharma Stock Performance
Shares of NASDAQ:LYEL opened at $3.04 on Tuesday. Lyell Immunopharma has a 1 year low of $2.74 and a 1 year high of $8.74. The stock has a market capitalization of $757.95 million, a P/E ratio of -3.42 and a beta of -1.91. The stock has a 50-day simple moving average of $3.53 and a 200-day simple moving average of $5.51.
Lyell Immunopharma (NASDAQ:LYEL – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06. Lyell Immunopharma had a negative return on equity of 29.54% and a negative net
margin of 660.62%. Analysts predict that Lyell Immunopharma will post -1 earnings per share for the current year.
Hedge Funds Weigh In On Lyell Immunopharma
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in Lyell Immunopharma by 76.1% in the 1st quarter. Royal Bank of Canada now owns 9,114 shares of the company's stock worth $46,000 after acquiring an additional 3,940 shares during the period. Nisa Investment Advisors LLC purchased a new position in shares of Lyell Immunopharma during the 2nd quarter valued at approximately $38,000. Baillie Gifford & Co. boosted its stake in shares of Lyell Immunopharma by 0.8% during the 4th quarter. Baillie Gifford & Co. now owns 761,321 shares of the company's stock valued at $2,642,000 after buying an additional 6,216 shares during the last quarter. American International Group Inc. boosted its stake in shares of Lyell Immunopharma by 10.0% during the 2nd quarter. American International Group Inc. now owns 80,983 shares of the company's stock valued at $528,000 after buying an additional 7,338 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of Lyell Immunopharma by 7.3% during the 3rd quarter. New York State Common Retirement Fund now owns 117,792 shares of the company's stock valued at $863,000 after buying an additional 8,050 shares during the last quarter. Hedge funds and other institutional investors own 45.04% of the company's stock.
Lyell Immunopharma Company Profile
(Get Rating)
Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
Featured Stories
- Get a free copy of the StockNews.com research report on Lyell Immunopharma (LYEL)
- When Will Crane Holdings Take Flight?
- Is It Time To Get Aggressive With Defense Stocks?
- 3 Retail Stocks Ringing the Register in 2023
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
